{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:45:27Z","timestamp":1792500327741,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.actbio.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T22:34:14Z","timestamp":1712702054000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"C","title":["Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6017","authenticated-orcid":false,"given":"Eliana B.","family":"Souto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-0306","authenticated-orcid":false,"given":"Cristina","family":"Blanco-Llamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-4020","authenticated-orcid":false,"given":"Karolline","family":"Krambeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-3254","authenticated-orcid":false,"given":"Neelakanta Sarvashiva","family":"Kiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekar","family":"Yashaswini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humzah","family":"Postwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-0405","authenticated-orcid":false,"given":"Ronny","family":"Priefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":false,"given":"Bhupendra Gopalbhai","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-9461","authenticated-orcid":false,"given":"Rahul","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2024.04.010_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4927312","article-title":"Cancer nanomedicine: a new era of successful targeted therapy","volume":"2019","author":"El-Readi","year":"2019","journal-title":"J. Nanomater."},{"issue":"11","key":"10.1016\/j.actbio.2024.04.010_bib0002","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.actbio.2024.04.010_bib0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2217\/nnm-2018-0147","article-title":"Nanoparticle systems for cancer vaccine","volume":"14","author":"Wen","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2024.04.010_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2020.03.015","article-title":"Nanoparticle mediated cancer immunotherapy","volume":"69","author":"Gupta","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0006","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jconrel.2023.02.015","article-title":"Vaccine-like nanomedicine for cancer immunotherapy","volume":"355","author":"Yi","year":"2023","journal-title":"J. Controll. Release"},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0007","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.actbio.2024.04.010_bib0008","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/cgt.2015.58","article-title":"Gene therapy for cancer: regulatory considerations for approval","volume":"22","author":"Husain","year":"2015","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.actbio.2024.04.010_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jgf2.321","article-title":"Ethical considerations of gene editing and genetic selection","volume":"21","author":"Rothschild","year":"2020","journal-title":"J. Gen. Fam. Med."},{"key":"10.1016\/j.actbio.2024.04.010_bib0011","article-title":"Nanodelivery of nucleic acids","volume":"24","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers."},{"key":"10.1016\/j.actbio.2024.04.010_bib0012","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.apsb.2023.05.016","article-title":"Light-responsive nanomedicine for cancer immunotherapy","volume":"13","author":"Kang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0013","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acs.accounts.0c00456","article-title":"Engineered Nanoparticles for Cancer Vaccination and Immunotherapy","volume":"53","author":"Aikins","year":"2020","journal-title":"Acc. Chem. Res."},{"issue":"7","key":"10.1016\/j.actbio.2024.04.010_bib0014","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.actbio.2024.04.010_bib0015","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","article-title":"Current research trends of nanomedicines","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.actbio.2024.04.010_bib0016","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/bs.ircmb.2022.04.010","article-title":"mRNA delivery technologies: toward clinical translation","volume":"372","author":"G\u00f3mez-Aguado","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0017","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.3390\/ijms24097736","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.actbio.2024.04.010_bib0019","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control Release"},{"issue":"6","key":"10.1016\/j.actbio.2024.04.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202204932","article-title":"Hybrid nanomaterials for cancer immunotherapy","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2024.04.010_bib0021","series-title":"Endothelial-Targeted Gene Regulation For Angiogenic Therapy","author":"Mushimiyimana","year":"2023"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12985-022-01957-1","article-title":"Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine","volume":"19","author":"Wang","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.actbio.2024.04.010_bib0023","first-page":"1","article-title":"E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2","author":"Zhang","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.actbio.2024.04.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chas.3c00104","article-title":"Advancing era and rising concerns in nanotechnology-based cancer treatment","author":"Tiwari","year":"2024","journal-title":"ACS Chem. Health Saf."},{"key":"10.1016\/j.actbio.2024.04.010_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/9781394175482.ch13","article-title":"Nanovaccines for veterinary applications","author":"Vuppu","year":"2024","journal-title":"Nanocarrier Vacc."},{"key":"10.1016\/j.actbio.2024.04.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115992","article-title":"Nanovaccines: an effective therapeutic approach for cancer therapy","volume":"170","author":"Gurunathan","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.actbio.2024.04.010_bib0027","series-title":"Nanocarrier Vacc.","first-page":"465","article-title":"Regulatory pathways for nanocarrier vaccine","author":"Gogoi","year":"2024"},{"key":"10.1016\/j.actbio.2024.04.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.3c10623","article-title":"A versatile nanovaccine enhancement strategy based on suction-inspired physical therapy","author":"Wu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0029","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","article-title":"Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications","volume":"343","author":"Bhattacharjee","year":"2022","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.actbio.2024.04.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2023.200254","article-title":"The adenoviral E4orf3\/4 is a regulatory polypeptide with cell transforming properties in vitro","volume":"15","author":"Ip","year":"2023","journal-title":"Tumour. Virus. Res."},{"key":"10.1016\/j.actbio.2024.04.010_bib0031","series-title":"Oncogenic Viruses","first-page":"387","article-title":"In vivo gene therapy with p53 or p21 adenovirus for prostate cancer","author":"Boussettine","year":"2023"},{"key":"10.1016\/j.actbio.2024.04.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0033","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41417-022-00469-y","article-title":"Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses","volume":"29","author":"Thambi","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.actbio.2024.04.010_bib0034","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"key":"10.1016\/j.actbio.2024.04.010_bib0035","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1007\/s12274-022-5002-2","article-title":"Recent advances of bioresponsive polymeric nanomedicine for cancer therapy","volume":"16","author":"Hong","year":"2022","journal-title":"Nano Res."},{"issue":"15","key":"10.1016\/j.actbio.2024.04.010_bib0036","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1080\/00914037.2019.1655745","article-title":"Polymer-drug conjugates as nanomedicine: a review","volume":"69","author":"Girase","year":"2020","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"issue":"13","key":"10.1016\/j.actbio.2024.04.010_bib0037","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1021\/acs.chemrev.1c00009","article-title":"Thermostability, tunability, and tenacity of RNA as rubbery anionic polymeric materials in nanotechnology and nanomedicine\u2014specific cancer targeting with undetectable toxicity","volume":"121","author":"Binzel","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.actbio.2024.04.010_bib0038","series-title":"Polymeric Nanoparticles for Intraperitoneal Cancer Treatment: Development and Characterisation of a Novel Drug Delivery Platform","author":"Hyldbakk","year":"2023"},{"key":"10.1016\/j.actbio.2024.04.010_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","article-title":"Polymeric micelles in cancer therapy: state of the art","volume":"332","author":"Ghosh","year":"2021","journal-title":"J. Control Release"},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4155\/tde-2020-0008","article-title":"Polymeric micelles for anticancer drug delivery","volume":"11","author":"Majumder","year":"2020","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0041","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1080\/21691401.2019.1601104","article-title":"Intelligent polymeric micelles for multidrug co-delivery and cancer therapy","volume":"47","author":"Yu","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0042","article-title":"Multi-functional chitosan polymeric micelles as oral paclitaxel delivery systems for enhanced bioavailability and anti-tumor efficacy","volume":"578","author":"Tu","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.actbio.2024.04.010_bib0043","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1039\/C9BM02010A","article-title":"Stabilization of indocyanine green dye in polymeric micelles for NIR-II fluorescence imaging and cancer treatment","volume":"8","author":"Yeroslavsky","year":"2020","journal-title":"Biomater. Sci."},{"issue":"7","key":"10.1016\/j.actbio.2024.04.010_bib0044","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/03639045.2021.1983585","article-title":"Brigatinib loaded poly (d, l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines","volume":"47","author":"Ahmed","year":"2021","journal-title":"Drug Dev. Ind. Pharmacy"},{"issue":"26","key":"10.1016\/j.actbio.2024.04.010_bib0045","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/j.biomaterials.2006.04.026","article-title":"Nanoparticulate drug carriers based on hybrid poly (D, l-lactide-co-glycolide)-dendron structures","volume":"27","author":"Costantino","year":"2006","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0046","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1166\/jbn.2020.2883","article-title":"Selective tumor-specific antigen delivery to dendritic cells using mannose-labeled poly (d, l-lactide-co-glycolide) nanoparticles for cancer immunotherapy","volume":"16","author":"Wi","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118747","article-title":"Stimulus-responsive drug\/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy","volume":"276","author":"Mousazadeh","year":"2022","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0048","first-page":"125","article-title":"Preparation and characterization of PLA-PEG-PLA\/PEI\/DNA nanoparticles for improvement of transfection efficiency and controlled release of DNA in gene delivery systems","volume":"18","author":"Amani","year":"2019","journal-title":"Iran. J. Pharmac. Res."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0049","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/10717544.2018.1461957","article-title":"Preparation of poly-l-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo","volume":"25","author":"Yang","year":"2018","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.actbio.2024.04.010_bib0050","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/ijms23031492","article-title":"Poly-l-lysine\u2013lactobionic acid-capped selenium nanoparticles for liver-targeted gene delivery","volume":"23","author":"Naidoo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0051","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0052","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2024.04.010_bib0053","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","article-title":"Future considerations for the mRNA-lipid nanoparticle vaccine platform","volume":"48","author":"Igy\u00e1rt\u00f3","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0054","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2022.08.009","article-title":"A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs","volume":"350","author":"Bogaert","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2024.04.010_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114962","article-title":"Evolution of nanomedicine formulations for targeted delivery and controlled release","author":"Puri","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.actbio.2024.04.010_bib0056","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS. Nano"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0057","first-page":"11","article-title":"Delivery strategies for mRNA vaccines","volume":"36","author":"Ramachandran","year":"2022","journal-title":"Pharmaceut. Med."},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0058","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/pharmaceutics12020161","article-title":"Perillaldehyde 1,2-epoxide Loaded SLN-tailored mAb: production, physicochemical characterization and in vitro cytotoxicity profile in MCF-7 cell lines","volume":"12","author":"Souto","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.actbio.2024.04.010_bib0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2014.09.021","article-title":"Development and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy","volume":"66","author":"Severino","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.actbio.2024.04.010_bib0060","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1021\/acsnano.9b01774","article-title":"The skin you are in: design-of-experiments optimization of lipid nanoparticle self-amplifying RNA formulations in human skin explants","volume":"13","author":"Blakney","year":"2019","journal-title":"ACS. Nano"},{"issue":"4","key":"10.1016\/j.actbio.2024.04.010_bib0061","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0062","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.smaim.2022.11.001","article-title":"Advances in mRNA nanomedicines for malignant brain tumor therapy","volume":"4","author":"Deng","year":"2023","journal-title":"Smart. Mater. Med."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0063","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2302\/kjm.71-001-ABST","article-title":"Developing mRNA for therapy","volume":"71","author":"Karik\u00f3","year":"2022","journal-title":"Keio J. Med."},{"key":"10.1016\/j.actbio.2024.04.010_bib0064","article-title":"Nanomedicine: a pragmatic approach for tackling melanoma skin cancer","volume":"83","author":"Prajapat","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106476","article-title":"A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma","volume":"187","author":"Rahimi","year":"2023","journal-title":"Eur. J. Pharmac. Sci."},{"key":"10.1016\/j.actbio.2024.04.010_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.137147","article-title":"Nanomedicines and nanomaterials for cancer therapy: progress, challenge and perspectives","volume":"446","author":"Jing","year":"2022","journal-title":"Chem. Eng. J."},{"issue":"6","key":"10.1016\/j.actbio.2024.04.010_bib0067","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.molmed.2021.03.003","article-title":"Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines","volume":"27","author":"Swingle","year":"2021","journal-title":"Trends. Mol. Med."},{"issue":"3","key":"10.1016\/j.actbio.2024.04.010_bib0068","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2174\/157341311795542453","article-title":"Liposomes: a review of manufacturing techniques and targeting strategies","volume":"7","author":"Maherani","year":"2011","journal-title":"Curr. Nanosci."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0069","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1080\/10717544.2022.2139021","article-title":"Design and applications of liposome-in-gel as carriers for cancer therapy","volume":"29","author":"Mou","year":"2022","journal-title":"Drug Deliv."},{"issue":"13","key":"10.1016\/j.actbio.2024.04.010_bib0070","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1007\/s00018-021-03850-6","article-title":"Recent advances in liposome formulations for breast cancer therapeutics","volume":"78","author":"Yang","year":"2021","journal-title":"Cellular Mol. Life Sci."},{"key":"10.1016\/j.actbio.2024.04.010_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104143","article-title":"Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity","volume":"354","author":"Mai","year":"2020","journal-title":"Cell. Immunol."},{"issue":"23","key":"10.1016\/j.actbio.2024.04.010_bib0072","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","article-title":"Lipid nanoparticle-mRNA formulations for therapeutic applications","volume":"54","author":"Wang","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.actbio.2024.04.010_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2024.04.010_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107833","article-title":"Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model","volume":"98","author":"Yazdani","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0075","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41598-023-31007-x","article-title":"Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine","volume":"13","author":"Tahaghoghi-Hajghorbani","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.actbio.2024.04.010_bib0076","first-page":"1065","article-title":"Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy","volume":"23","author":"Yazdani","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0077","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12645-023-00213-7","article-title":"Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma","volume":"14","author":"Zahedipour","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101244","article-title":"Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment","volume":"40","author":"Tang","year":"2021","journal-title":"Nano Today"},{"issue":"34","key":"10.1016\/j.actbio.2024.04.010_bib0079","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in\u2005vivo**","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0080","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"21","key":"10.1016\/j.actbio.2024.04.010_bib0081","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/acs.accounts.1c00500","article-title":"Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing","volume":"54","author":"Qiu","year":"2021","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0082","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"issue":"34","key":"10.1016\/j.actbio.2024.04.010_bib0083","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.actbio.2024.04.010_bib0084","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.2c00010","article-title":"Current status and future perspectives on MRNA drug manufacturing","volume":"19","author":"Webb","year":"2022","journal-title":"Mol. Pharm."},{"issue":"19","key":"10.1016\/j.actbio.2024.04.010_bib0085","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.3390\/molecules25194377","article-title":"Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy","volume":"25","author":"Mohanty","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.actbio.2024.04.010_bib0086","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2017.12.016","article-title":"Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics","volume":"271","author":"Date","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2024.04.010_bib0087","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mimet.2019.03.017","article-title":"Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications","volume":"160","author":"Dave","year":"2019","journal-title":"J. Microbiol. Methods"},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0088","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.drudis.2018.05.033","article-title":"Lipid\u2013polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions","volume":"23","author":"Garg","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0089","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","article-title":"Nanocarriers based on bacterial membrane materials for cancer vaccine delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1039\/D0NH00267D","article-title":"Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications","volume":"5","author":"Liao","year":"2020","journal-title":"Nanoscale Horiz."},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0091","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsnano.0c09382","article-title":"Hybrid nanosystems for biomedical applications","volume":"15","author":"Seaberg","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0092","article-title":"Dendrimer applications for cancer therapies","author":"Yan","year":"2021","journal-title":"J. Phys."},{"key":"10.1016\/j.actbio.2024.04.010_bib0093","series-title":"Polymeric Nanoparticles as a Promising Tool for Anti-Cancer Therapeutics","first-page":"233","article-title":"Dendrimer-based nanoparticulate delivery system for cancer therapy","author":"Shukla","year":"2019"},{"key":"10.1016\/j.actbio.2024.04.010_bib0094","series-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer","first-page":"161","article-title":"Dendrimer-based nanocarriers in lung cancer therapy","author":"Gorain","year":"2019"},{"issue":"10","key":"10.1016\/j.actbio.2024.04.010_bib0095","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.3390\/molecules27103237","article-title":"Application of dendrimers in anticancer diagnostics and therapy","volume":"27","author":"Bober","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.actbio.2024.04.010_bib0096","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2147\/IJN.S112660","article-title":"Carbon nanotubes as cancer therapeutic carriers and mediators","volume":"11","author":"Son","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2024.04.010_bib0097","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/837327","article-title":"Carbon nanotubes in cancer therapy and drug delivery","volume":"2012","author":"Elhissi","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.actbio.2024.04.010_bib0098","series-title":"Handbook of Carbon Nanotubes","first-page":"1739","article-title":"Carbon nanotubes in cancer therapy","author":"Ravi Kiran","year":"2022"},{"issue":"4","key":"10.1016\/j.actbio.2024.04.010_bib0099","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5958\/0975-4377.2020.00050.6","article-title":"Carbon nanotubes as an effective solution for cancer therapy","volume":"12","author":"Yadav","year":"2020","journal-title":"Res. J. Pharmac. Dosage Forms Technol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jconrel.2019.01.017","article-title":"Application of carbon nanotubes in cancer vaccines: achievements, challenges and chances","volume":"297","author":"Hassan","year":"2019","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2024.04.010_bib0101","article-title":"Carbon nanotubes in drug delivery: focus on anticancer therapies","volume":"59","author":"Kiran","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0102","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/pharmaceutics11090486","article-title":"Injectable hydrogels for cancer therapy over the last decade","volume":"11","author":"Cirillo","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.actbio.2024.04.010_bib0103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3389\/fchem.2019.00675","article-title":"Injectable hydrogels for localized cancer therapy","volume":"7","author":"Fan","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.actbio.2024.04.010_bib0104","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijbiomac.2019.08.031","article-title":"A novel biocompatible core-shell magnetic nanocomposite based on cross-linked chitosan hydrogels for in vitro hyperthermia of cancer therapy","volume":"140","author":"Eivazzadeh-Keihan","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eml.2021.101305","article-title":"Programmable shape transformation of 3D printed magnetic hydrogel composite for hyperthermia cancer therapy","volume":"46","author":"Tang","year":"2021","journal-title":"Extreme Mech. Lett."},{"key":"10.1016\/j.actbio.2024.04.010_bib0106","article-title":"Potential of supercritical fluid myrtle extracts as an active ingredient and co-preservative for cosmetic and topical pharmaceutical applications","volume":"28","author":"Pereira","year":"2022","journal-title":"Sustain. Chem. Pharm."},{"key":"10.1016\/j.actbio.2024.04.010_bib0107","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jddst.2018.12.010","article-title":"Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis","volume":"49","author":"Kulkarni","year":"2019","journal-title":"J. Drug Deliv. Sci. Technology"},{"key":"10.1016\/j.actbio.2024.04.010_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.giant.2021.100073","article-title":"Nanocomposite of Au and black phosphorus quantum dots as versatile probes for amphibious SERS spectroscopy, 3D photoacoustic imaging and cancer therapy","volume":"8","author":"Chen","year":"2021","journal-title":"Giant"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/17425247.2012.638624","article-title":"Quantum dots in cancer therapy","volume":"9","author":"Luo","year":"2012","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.actbio.2024.04.010_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.matlet.2022.131742","article-title":"Bioinspired quantum dots for cancer therapy: a mini-review","author":"Kumar","year":"2022","journal-title":"Mater. Lett."},{"key":"10.1016\/j.actbio.2024.04.010_bib0111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fmats.2021.798440","article-title":"Quantum dots: an emerging approach for cancer therapy","volume":"8","author":"Devi","year":"2022","journal-title":"Front. Mater."},{"issue":"4","key":"10.1016\/j.actbio.2024.04.010_bib0112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/jfb12040075","article-title":"Quantum dots: synthesis, antibody conjugation, and HER2-receptor targeting for breast cancer therapy","volume":"12","author":"Fatima","year":"2021","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.actbio.2024.04.010_bib0113","article-title":"Antigen self-presented personalized nanovaccines boost the immunotherapy of highly invasive and metastatic tumors","author":"Wang","year":"2024","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0114","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1021\/acsnano.4c01050","article-title":"Biologically self-assembled tumor cell-derived cancer nanovaccines as an all-in-one platform for cancer immunotherapy","volume":"18","author":"Liang","year":"2024","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.148611","article-title":"Cancer cell membrane proteins-encapsulated nanovaccine enhances cancer immunotherapy and prevention by provoking antigen-specific cellular immunity via the dendritic cell-targeted delivery","volume":"481","author":"Luo","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2024.04.010_bib0116","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS. Nano"},{"key":"10.1016\/j.actbio.2024.04.010_bib0117","first-page":"330","article-title":"Engineering customized nanovaccines for enhanced cancer immunotherapy","volume":"36","author":"Guo","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.actbio.2024.04.010_bib0118","article-title":"Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy","volume":"25","author":"Zheng","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0119","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12951-024-02345-3","article-title":"Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0120","first-page":"1","article-title":"Co-delivery of brinzolamide and timolol from micelles-laden contact lenses: in vitro and in vivo evaluation","author":"Yang","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2024.04.010_bib0121","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.biomac.3c01235","article-title":"pH and ROS responsiveness of polymersome nanovaccines for antigen and adjuvant codelivery: an in vitro and in vivo comparison","volume":"25","author":"J\u00e4ger","year":"2024","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.actbio.2024.04.010_bib0122","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.vaccine.2023.12.079","article-title":"Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold","volume":"42","author":"Peng","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.actbio.2024.04.010_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122480","article-title":"Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma","volume":"306","author":"Shi","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2024.04.010_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2024.102738","article-title":"Engineered photonic near-infrared light activated photothermal theranostic nanovaccine induced targeted remodeling of tumor microenvironment","author":"Gowsalya","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2024.04.010_bib0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/IJN.S438359","article-title":"Enhancing dendritic cell activation through manganese-coated nanovaccine targeting the cGAS-STING pathway","author":"Wang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2024.04.010_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149540","article-title":"In vitro and in vivo study of andrographolide nanoparticles for the treatment of Mycoplasma pneumoniae pneumonia","volume":"698","author":"Wang","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.actbio.2024.04.010_bib0127","doi-asserted-by":"crossref","first-page":"eadk2444","DOI":"10.1126\/sciadv.adk2444","article-title":"Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy","volume":"10","author":"Liu","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-024-02354-2","article-title":"Smart responsive Fe\/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation","volume":"22","author":"Du","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111543","article-title":"Peptide nanovaccine in melanoma immunotherapy","volume":"129","author":"Dehghankhold","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0130","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1021\/acsnano.3c11637","article-title":"Self-adjuvanting polyguanidine nanovaccines for cancer immunotherapy","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"issue":"15_suppl","key":"10.1016\/j.actbio.2024.04.010_bib0131","doi-asserted-by":"crossref","first-page":"TPS9135","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9135","article-title":"Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC","volume":"39","author":"Lisberg","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.actbio.2024.04.010_bib0132","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.3390\/cancers14205163","article-title":"Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments","volume":"14","author":"Niemi","year":"2022","journal-title":"Cancers"},{"issue":"15_suppl","key":"10.1016\/j.actbio.2024.04.010_bib0133","doi-asserted-by":"crossref","first-page":"TPS9107","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107","article-title":"Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"36","author":"Gandhi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7823","key":"10.1016\/j.actbio.2024.04.010_bib0134","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"16_suppl","key":"10.1016\/j.actbio.2024.04.010_bib0136","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2022.40.16_suppl.5068","article-title":"A pilot trial of neoantigen DNA vaccine in combination with nivolumab\/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0137","article-title":"Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment","volume":"11","author":"Liao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0138","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/vaccines11010146","article-title":"Cancer vaccines for triple-negative breast cancer: a systematic review","author":"Hosseini","year":"2023","journal-title":"Vaccines"},{"issue":"16_suppl","key":"10.1016\/j.actbio.2024.04.010_bib0139","doi-asserted-by":"crossref","first-page":"e21542","DOI":"10.1200\/JCO.2022.40.16_suppl.e21542","article-title":"IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional \u201cin-situ vaccine\u201d approach","volume":"40","author":"Markowitz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0140","article-title":"Nanotechnology-assisted immunoengineering for cancer vaccines","volume":"3","author":"Mamuti","year":"2023","journal-title":"J. Adv. NanoBiomed. Res."},{"issue":"15_suppl","key":"10.1016\/j.actbio.2024.04.010_bib0141","doi-asserted-by":"crossref","first-page":"TPS6093","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS6093","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.actbio.2024.04.010_bib0143","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3889\/oamjms.2019.486","article-title":"The role of nanomaterials in the treatment of diseases and their effects on the immune system","volume":"7","author":"Rezaei","year":"2019","journal-title":"Open Access. Maced. J. Med. Sci."},{"key":"10.1016\/j.actbio.2024.04.010_bib0144","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.glohj.2023.02.008","article-title":"Applications of nanotechnology in medical field: a brief review","volume":"7","author":"Haleem","year":"2023","journal-title":"Global Health J."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0145","doi-asserted-by":"crossref","first-page":"e1531","DOI":"10.1002\/wnan.1531","article-title":"Mapping of the available standards against the regulatory needs for nanomedicines, Wiley interdisciplinary reviews","volume":"11","author":"Halamoda-Kenzaoui","year":"2019","journal-title":"Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0146","first-page":"172","article-title":"Importance of standardizing analytical characterization methodology for improved reliability of the nanomedicine literature","volume":"14","author":"Sharifi","year":"2022","journal-title":"Nanomicro Lett."},{"issue":"9","key":"10.1016\/j.actbio.2024.04.010_bib0147","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s13346-022-01208-4","article-title":"Regulatory safety evaluation of nanomedical products: key issues to refine","volume":"12","author":"De Jong","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/vaccines9020081","article-title":"Development of mRNA vaccines: scientific and regulatory issues","volume":"9","author":"Knezevic","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.actbio.2024.04.010_bib0149","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/2231-4040.82952","article-title":"Intellectual property rights: an overview and implications in pharmaceutical industry","volume":"2","author":"Saha","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"5","key":"10.1016\/j.actbio.2024.04.010_bib0150","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020891","article-title":"Patentability of genes: a European Union perspective","volume":"5","author":"Cole","year":"2014","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"issue":"42","key":"10.1016\/j.actbio.2024.04.010_bib0151","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2021.08.101","article-title":"Collaboration in times of crisis: a study on COVID-19 vaccine R&D partnerships","volume":"39","author":"Druedahl","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.actbio.2024.04.010_bib0152","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12889-021-10374-y","article-title":"The role of intellectual property rights on access to medicines in the WHO African region: 25\u2009years after the TRIPS agreement","volume":"21","author":"Motari","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.actbio.2024.04.010_bib0153","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1007\/s10961-022-09958-6","article-title":"Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries","volume":"48","author":"Bhatnagar","year":"2023","journal-title":"J. Technol. Transf."},{"issue":"7","key":"10.1016\/j.actbio.2024.04.010_bib0154","article-title":"The role of regulatory agencies and intellectual property: Part I","volume":"5","author":"Noonan","year":"2015","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.actbio.2024.04.010_bib0155","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01526","article-title":"Impact of vaccines; health, economic and social perspectives","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.actbio.2024.04.010_bib0156","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev-genom-082509-141811","article-title":"Patents in genomics and human genetics","volume":"11","author":"Cook-Deegan","year":"2010","journal-title":"Annu Rev. Genomics. Hum. Genet."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T02:12:44Z","timestamp":1716430364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":156,"alternative-id":["S1742706124001831"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.04.010","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}